Collaboration and Stock Purchase Agreements (Narrative) (Details) $ in Thousands |
3 Months Ended | |||
|---|---|---|---|---|
|
Feb. 24, 2021
USD ($)
Milestone
|
Mar. 31, 2022
USD ($)
|
Mar. 31, 2021
USD ($)
|
Dec. 31, 2021
USD ($)
|
|
| Collaboration revenue | $ 577 | $ 800 | ||
| Accumulated deficit | (563,223) | $ (547,463) | ||
| Cash and cash equivalents | 287,511 | 289,897 | $ 305,744 | |
| Cyprium [Member] | Sentynl Therapeutics, Inc [Member] | ||||
| Upfront fees payment | $ 8,000 | |||
| Payments of milestones | $ 12,000 | |||
| Percentage of ownership over any FDA priority review voucher | 100.00% | |||
| Number of net sales milestones | Milestone | 5 | |||
| Collaboration revenue | $ 600 | $ 800 | ||
| FDA approval of the NDA [Member] | Cyprium [Member] | Sentynl Therapeutics, Inc [Member] | ||||
| Payments of milestones | $ 9,000 | |||
| Achievement of Certain Sales Milestones [Member] | Cyprium [Member] | Sentynl Therapeutics, Inc [Member] | ||||
| Payments of milestones | 255,000 | |||
| Completion of Clinical Development Milestones [Member] | Cyprium [Member] | Sentynl Therapeutics, Inc [Member] | ||||
| Payments of milestones | $ 3,000 | |||
| X | ||||||||||
- Definition Collaboration revenue. No definition available.
|
| X | ||||||||||
- Definition Number of net sales milestones of an entity during the period. No definition available.
|
| X | ||||||||||
- Definition Payment of Upfront Fees No definition available.
|
| X | ||||||||||
- Definition It represents payments of milestone. No definition available.
|
| X | ||||||||||
- Definition Percentage of ownership over any FDA priority review voucher No definition available.
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|